ASX Filings

Ceasing to be a substantial holder

March 13, 2017

Opthea Completes FDA Meeting to Inform OPT-302 Program

March 9, 2017

Opthea Half Year Report and Accounts

February 21, 2017

Change in substantial holding

February 14, 2017

Appendix 3B

February 6, 2017

Opthea Corporate Presentation during JPMorgan Conference

January 9, 2017

Opthea CEO Presentation to the 2016 AGM

November 28, 2016

Opthea Chairman's Address to the 2016 AGM

November 28, 2016

Results of Meeting

November 28, 2016

Opthea Completes Patient Enrolment in Ph1/2A wAMD Trial

November 21, 2016